Hit to Lead for SARS-CoV-2
At present, the drug research for treating Coronavirus Disease 2019 (COVID-19) has just started, and there is a lack of selective therapeutic drugs in clinical practice. It is urgent to find and develop new treatment methods and drugs. In the face of urgent outbreaks, it is an efficient strategy to screen potential drug candidates from old drugs that are already on the market or from active molecules in clinical trials. Considering the threat of coronavirus infection to humans, we should not only actively seek specific antiviral drugs, but also promote the development of new broad-spectrum anti-coronavirus drugs. After hit identification, Creative Biostructure provides a full range of hit-to-lead services to support your antiviral drug discovery project against coronavirus infection.